ASCLS Webinar - Optimizing Liver Function Test Interpretation in NAFLD: Transaminases, Uric Acid, an

Presenter: Mark Kellogg, PhD, MLS(ASCP), DABCC, Associate Director of Chemistry at Boston Children’s Hospital

Description: This presentation examines the complexities of liver function test interpretation in non-alcoholic fatty liver disease (NAFLD), with emphasis on understanding transaminase reference intervals and the emerging role of uric acid as a biomarker. The session addresses a critical gap in clinical practice: up to 86 percent of NAFLD patients may present with normal ALT levels, yet many providers rely solely on traditional reference ranges for screening and monitoring. Through case-based discussion and evidence review, participants will learn practical strategies for accurate test interpretation and how targeted provider education can improve early detection and management of NAFLD.

Objectives:

1. Evaluate the clinical significance of serum uric acid levels as an independent risk factor for NAFLD development and progression, understanding the 2.1-fold increased odds associated with hyperuricemia.

2. Apply evidence-based strategies for monitoring patients with NAFLD using appropriate intervals for liver enzyme reassessment, fibrosis scoring, and specialist referral criteria.

3. Implement provider education interventions that address common misinterpretations of liver function tests and promote guideline-concordant care for NAFLD patients.

Instruction Level: Intermediate

Registration: Free for ASCLS members; $10 for non-members